Do you want to read an article? Please log in or register.
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma
Further Publications
Related content
Lymphoma
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201
Leuk Lymphoma
Andreadis C, Bobek O, Hsi ED, Fenske TS, Stiff PJ, Hill BT, Geyer SM, Horwitz M, Khimani F, Little RF, Dinner SN, Friedberg JW, Kahl BS, Perales MA, Devine SM, Leonard JP, Bartlett NL
doi: 10.1080/10428194.2025.2525982
Lymphoma
Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial
Ann Oncol
Michot JM, Bologna S, Bastie JN, Borght TV, Brière J, Ribrag V, Bommier C, Peyrade F, Lebras L, Damaj G, Coso D, Sibon D, Bonnet C, Morschhauser F, Ghesquières H, Fruchart C, Soussain C, Becker S, Olivier P, Julian A, Molina T, Haioun C, Tilly H
doi: 10.1016/j.annonc.2025.11.006
Lymphoma
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma
Blood Cancer J
Shi W, Xu-Monette ZY, Jia Y, Tzankov A, Go H, Li L, Ponzoni M, Wang Y, Zhai Q, Perry AM, Wang S, Wang X, Chiu A, Xu ML, Visco C, Dybkaer K, Withers H, Long M, Yuan AF, Miao Y, Macias E, Wu D, Shuai W, Wang B, Li J, Bhagat G, Zu Y, Pan Z, Choi W, Montes-Moreno S, Chen W, Krieken JHV, Møller MB, Yu X, Parsons BM, Zhang S, Hsi ED, Sohani AR, Abramson JS, Ferreri AJM, Xu B, Li Y, Young KH
doi: 10.1038/s41408-025-01323-8
Lymphoma
Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)
Leuk Lymphoma
Phillips T, Zhou Z, Gutierrez C, Shao A, Boyd M, Noshad S, Hohlbauch A, Liu N, Repetny K, Fanale M, Mitchell B, Davis EA, Gennarelli R, Burke JM
doi: 10.1080/10428194.2025.2604300
Lymphoma
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma
J Clin Oncol
Wang S, Nijland M, Strobbe L, Oosterveld M, Boersma R, Koene H, Klerk C, de Jongh E, Koster A, Pruijt H, van der Poel M, van Werkhoven E, Zanders H, Dinmohamed A, Pegtel M, Meek S, Stowell SL, Warinske H, Alizadeh AA, Kurtz DM, Chamuleau MED
doi: 10.1200/JCO-25-01712
Lymphoma
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis
Am J Hematol
Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF
doi: 10.1002/ajh.70033
Lymphoma
Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study
Br J Haematol
Trab T, Ranadóttir T, Chanchiri I, Ludvigsen Al-Mashhadi A, Berggreen Dall E, Rasch S, Johansen M, Haunstrup LM, Cunsolo G, Poulsen CB, Larsen TS, Husby S, Brown P, Hawkes EA, El-Galaly TC, Grønbæk K
doi: 10.1111/bjh.70082
Lymphoma
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies
Am J Hematol
Atallah-Yunes SA, Nze CC, King RL, Rees MJ, Alderuccio JP, Watkins M, Kahl BS, Easwar N, Yamshon S, Ravindra A, Farooq U, Rosenthal AC, Munoz JL, Rojas-Neira EM, Ayers AA, Moustafa MA, Habermann TM, Witzig TE, Ansell SM, Nowakowski GS, Koff JL, Flowers CR, Wang Y
doi: 10.1002/ajh.70058
COMMENTED
Lymphoma
Treatment and outcome of breast implant-associated anaplastic large cell lymphoma: a population-based cohort study in the Netherlands
★ 1
Recommended and commented by
Dr Andreas Müller, Faculty Member
Leuk Lymphoma
Meeuwes FO, Brink M, van der Poel MWM, Serroukh YIM, Vermaat JSP, Huls GA, de Boer M, de Jong D, Plattel WJ, Nijland M
doi: 10.1080/10428194.2025.2530167